Researchers studying 278 patients with in-stent restenosis found that B. Braun‘s SeQuent Please paclitaxel-eluting balloon was non-inferior to Abbott‘s (NYSE:ABT) Xience drug-eluting stent when it comes to six-month minimal lumen diameter.
The study’s results were touted this week at the annual Transcatheter Cardiovascular Therapeutics conference in Denver, Colorado.
Researchers found that treatment with a drug-eluting stent yielded larger in-segment minimal lumen diameter and a lower rate of stenosis. The group treated with a drug-eluting stent had late lumen loss of 0.45 – 0.17mm after six months.
Death, myocardial infarction and stroke occurred at comparable rates between both treatment groups.
“In patients with ISR, treatment with DEB was non-inferior compared with DES in terms of six-month minimal lumen diameter,” the researchers wrote in JACC: Cardiovascular Interventions. “There were no differences in clinical endpoints, including target vessel revascularization up to 12 months. Therefore, use of a DEB is an attractive treatment option for ISR which negates the need for additional stent implantation.”
